09:49 EST 21st January 2018 | BioPortfolio

SAN-300, its novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule which plays a key role at sites of chronic inflammation. SAN-300 has potential application as a drug candidate in multiple inflammatory and autoimmune diseases, including Rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

SAN-300 was originally developed by Biogen Idec. In January 2009, Biogen licensed the antibody to Covella Pharmaceuticals and the deal was amended when Santarus acquired Covella in September 2010. In January 2014, Salix gained rights to the antibody, following its acquisition of Santarus.

Quick Search


review and buy SAN-300 market research data and corporate reports here